JPH0283318A - Stable eye drop - Google Patents
Stable eye dropInfo
- Publication number
- JPH0283318A JPH0283318A JP63233564A JP23356488A JPH0283318A JP H0283318 A JPH0283318 A JP H0283318A JP 63233564 A JP63233564 A JP 63233564A JP 23356488 A JP23356488 A JP 23356488A JP H0283318 A JPH0283318 A JP H0283318A
- Authority
- JP
- Japan
- Prior art keywords
- polyoxyethylene
- quaternary ammonium
- chondroitin sulfate
- eye drops
- ammonium salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 42
- -1 polyoxyethylene Polymers 0.000 claims abstract description 31
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims abstract description 20
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 16
- 229930195729 fatty acid Natural products 0.000 claims abstract description 16
- 239000000194 fatty acid Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 10
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 10
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 10
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims abstract description 9
- 229960001950 benzethonium chloride Drugs 0.000 claims abstract description 9
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 7
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004359 castor oil Substances 0.000 claims abstract description 7
- 235000019438 castor oil Nutrition 0.000 claims abstract description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 7
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims abstract description 6
- 229940012356 eye drops Drugs 0.000 claims description 26
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 239000008213 purified water Substances 0.000 abstract description 14
- 238000002156 mixing Methods 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 abstract 6
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 abstract 3
- 229960003720 enoxolone Drugs 0.000 abstract 3
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 9
- 229910021538 borax Inorganic materials 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000004328 sodium tetraborate Substances 0.000 description 7
- 235000010339 sodium tetraborate Nutrition 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- 239000004327 boric acid Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 4
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 4
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 4
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229920002567 Chondroitin Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- BFFQFGGITJXTFP-UHFFFAOYSA-N 3-methyldioxetane Chemical compound CC1COO1 BFFQFGGITJXTFP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- XLRHXNIVIZZOON-WFUPGROFSA-L Flavin adenine dinucleotide disodium Chemical compound [Na+].[Na+].C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 XLRHXNIVIZZOON-WFUPGROFSA-L 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960001983 magnesium aspartate Drugs 0.000 description 1
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 1
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は塩化ベンザルコニウム、塩化ヘンゼトニウムな
どの第４級アンモニウム塩類及びコンドロイチン硫酸ナ
トリウムを配合する点眼剤に間し。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention is directed to eye drops containing quaternary ammonium salts such as benzalkonium chloride and henzethonium chloride and sodium chondroitin sulfate.
さらに詳しくは上記成分を配合した白濁、沈澱を生しな
い安定な点１１Ｍ剤に関するものである。More specifically, it relates to a stable point 11M agent that does not cause cloudiness or precipitation, which contains the above-mentioned components.
［従来技術及び発明が解決しようとする問題点］点眼剤
は無菌的環境で製造されるが、消費者が購入後に生じる
二次汚染の可能性を考慮して防腐剤が配合されている。[Prior Art and Problems to be Solved by the Invention] Eye drops are manufactured in a sterile environment, but preservatives are added in consideration of the possibility of cross-contamination after purchase by consumers.
点眼剤に配合される防腐剤としてはパラオギン安息香酸
アルキルエステルいわゆるバラヘン類を初めとしてクロ
ロブタノール、グルコン酸り［ｌルヘキシジン、また塩
化ベンザルコニウム、塩化ベンゼトニウムなとの第４級
アンモニウム塩類などがある。特に塩化ヘンザルコニウ
ム、塩化ヘンセトニラムなとの第４級アンモニウム塩類
は広い抗菌スペクトルを持ち安全性も高いために多くの
点眼剤に使用されている。Preservatives used in eye drops include paraogine benzoic acid alkyl esters, so-called parahens, chlorobutanol, gluconate [lhexidine], and quaternary ammonium salts such as benzalkonium chloride and benzethonium chloride. . In particular, quaternary ammonium salts such as henzalkonium chloride and hensethonilam chloride have a broad antibacterial spectrum and are highly safe, so they are used in many eye drops.
一方、コンドロイチン＠酸ナトリウムは動物の軟骨、腰
、血管壁などの間葉組織中の構成成分とする酸性ムコ多
糖類であり体組織を強固にすると同時に、組織における
個々の細胞の新陳代謝を促進する成分であり、角膜コラ
ーゲン線維の安定化。On the other hand, sodium chondroitate is an acidic mucopolysaccharide that is a component of mesenchymal tissues such as animal cartilage, hips, and blood vessel walls, and it strengthens body tissues while promoting the metabolism of individual cells in the tissues. component and stabilizes corneal collagen fibers.
旧ＩＩ復、角膜浸潤防止、眼の各組織の機能保持を目的
として点眼剤に配合されている。It is formulated into eye drops for the purpose of restoring old II, preventing corneal infiltration, and maintaining the functions of various tissues of the eye.
しかしながら、第４級アンモニウム塩類とコンドロイチ
ンｖｉ酸すｌ・リムを共に配合した場合、酸塩基反応に
より白濁や沈澱の生成が認められる。However, when quaternary ammonium salts and chondroitin vi acid sulfate/rim are mixed together, cloudiness and precipitation are observed due to acid-base reactions.
このため両者の配合を避けた処方組みがなされてきたが
、効果や価格などを考慮した場合この第４級アンモニウ
ム塩類とコンドロイチン硫酸ナトリムを共に配合する点
眼剤が望まれていた。For this reason, prescriptions have been created that avoid the combination of both, but in consideration of effectiveness and cost, eye drops that contain both quaternary ammonium salts and sodium chondroitin sulfate have been desired.
本発明は第４級アンモニラ１．塩類とコンドロイチン硫
酸ナトリムを共に配合した場合にも白濁や沈澱を防止し
安定な点口Ｒ剤を提供することを目的とする。The present invention uses quaternary ammonia 1. The purpose of the present invention is to provide a stable instillation R agent that prevents clouding and precipitation even when salts and sodium chondroitin sulfate are mixed together.
［問題を解決するための手段］
本発明片らは、前述の目的を達成する手段について鋭意
検討を重ねた結果、塩化ヘンザルコニウム、塩化ベンゼ
トニウムなとの第４級アンモニラ１１塩類とコンドロイ
チン硫酸ナトリムを共に配合した場合においても、グリ
チルリチン酸またはその塩を０．０１〜０． ５ｗ／ｖ
％、好ましくは０゜０５〜０．２５ｗ／ｖ％を配合する
ことにより白濁や沈澱の生しない安定な点眼剤を得るこ
とに成功した。またグリチルリチン酸またはその塩の代
わりにポリオキシエチレン硬化ヒマシ油、ボリオギシエ
チレンソルビタン脂肪酸エステル、ポリオキソエチレン
脂肪酸エステル、ボリオギシエチレンボ１１オキシプロ
ピレンエーテルの中から選ばれた１←トまたは２種以上
を合計０．０１〜０．５ｗ／ｖ％、好ましくはｌ）、０
５〜０．３５ｗ／ｖ％を配合することによっても白濁や
沈澱の生じない安定な点眼剤を得ることに成功した。[Means for Solving the Problems] As a result of intensive studies on means for achieving the above-mentioned object, the present invention has developed a method for combining quaternary ammonia 11 salts such as henzalkonium chloride and benzethonium chloride with sodium chondroitin sulfate. Even when blended, the amount of glycyrrhizic acid or its salt is 0.01 to 0. 5w/v
%, preferably 0.05 to 0.25 w/v%, we succeeded in obtaining a stable eye drop that does not produce cloudiness or precipitation. In addition, instead of glycyrrhizic acid or its salt, 1← or 2 selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxoethylene fatty acid ester, polyoxyethylene bo-11 oxypropylene ether total of 0.01 to 0.5 w/v%, preferably l), 0
Even by blending 5 to 0.35 w/v%, it was possible to obtain a stable eye drop that does not cause cloudiness or precipitation.
すなわち本発明は塩化ヘンザルコニウム、塩化ベンゼト
ニウムなどの第４級アンモニウム塩類とコンドロイチン
硫酸ナトリムを共に配合した場合にも白濁や沈澱を防止
し安定な点眼剤をｊに供するものである。That is, the present invention provides stable eye drops that prevent clouding and precipitation even when quaternary ammonium salts such as henzalkonium chloride and benzethonium chloride are combined with sodium chondroitin sulfate.
本発明において使用されるグリチルリチン酸またはその
塩としては、グリチルリチン酸、グリチルリチン酸二カ
リウム、グリチルリチン故モノアンモニウム等がある。Examples of glycyrrhizic acid or a salt thereof used in the present invention include glycyrrhizic acid, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, and the like.
また、ポリオキシエチレン硬化ヒマシ油としては、ニラ
コールＨＣＯ４０（日光ケミカルズ社製）、ニラコール
ＩＣ０５０く日光ケミカルズン土製）、ニラコールＨＣ
０６０（日光ケミカルズ社製）等、ポリオキシエチレン
ソルビタン脂肪酸エステルとしては、ニラコールＴ０１
ＯＮ１（日光ケミカルズ社製）等、ボノオギソエチレン
脂肪酸エステルとしては、ニラコールＭＹＳ ７］０
（口元ケミカルス゛社８り等ポリオキンエチレンポリオ
キンブロピレンエニテルとしては、ブルロニ・ツク Ｆ
６Ｆ＋（旭電化工業製）等が挙げられる。In addition, as polyoxyethylene hydrogenated castor oil, Niracol HCO40 (manufactured by Nikko Chemicals Co., Ltd.), Niracol IC050 (manufactured by Nikko Chemicals Co., Ltd.), Niracol HC
As polyoxyethylene sorbitan fatty acid esters such as 060 (manufactured by Nikko Chemicals), Nilacol T01
ON1 (manufactured by Nikko Chemicals Co., Ltd.) and other bonoogisoethylene fatty acid esters include Nilacol MYS 7]0
(Polyoquine ethylene polyoquine propylene niter such as Mouth Chemical Co., Ltd.
6F+ (manufactured by Asahi Denka Kogyo) and the like.
本発明の安定な点眼／１１１は１例え（Ｌコンドロイチ
ン６育酸ナトリウムを参看製へ（こ１容解し、これにグ
リチルリチン酸あるいはその塩、ポリオキシエチレン硬
化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エス
テル、ポリオキソエチレン脂肪酸エステル又はポリオキ
シエチレンポリオキシプロピレンエーテルを溶解した後
、塩イヒヘンザルコニウム。Stable eye drops/111 of the present invention is an example of (L-chondroitin 6 sodium chloride), glycyrrhizic acid or its salt, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester. , after dissolving polyoxoethylene fatty acid ester or polyoxyethylene polyoxypropylene ether, sarkonium salt.
塩化ベンゼトニウムなとの第４級アンモニウム塩類を添
加することによって得つれろ。Obtained by adding quaternary ammonium salts such as benzethonium chloride.
このようにして得られた安定な点眼剤は第４級アンモニ
ウム塩類の添加直後も、 ｌＥた経時的にも白濁や沈
澱は起こらず安定である。The stable eye drops thus obtained are stable without clouding or precipitation, both immediately after addition of the quaternary ammonium salt and over time.
本発明の安定な点眼剤には、必要に応じてエタノール、
プロピレングリコール等のアルコール類。The stable eye drops of the present invention optionally contain ethanol,
Alcohols such as propylene glycol.
はう酸、はう砂、 リン酸水素ナトリウム等の無機塩類
、グルタミン酸、アスパラギン酸マグネシウムなとのア
ミノ［ｆｆ、 フラビンアデニンジヌクレオチド等の
ビタミン類等も添加することができる。Inorganic salts such as mineral acid, sand, and sodium hydrogen phosphate, amino acids such as glutamic acid and magnesium aspartate, and vitamins such as flavin adenine dinucleotide can also be added.
本発明の詳細な説明するために以下実施例を挙げるが１
本発明はこれによって限定されるものではない。Examples are given below to explain the present invention in detail.
The present invention is not limited thereby.
（実施例１）
コンドロイチン硫酸ナトリウｌ、ｌｏｏＩＩ１ｇを精製
水に溶解しこれにグリチルリチン酸二カリウム２５０ｍ
ｇを溶解した後、塩化ベンザルコニウム１０％水ＮＨＯ
，１ｍｌを添加した。これＬこアミノエチルスルホン酸
５００ｍｚ、ボウ＃１．Ｏｇを溶解し、ホウ砂の適量を
加え ｐＨ７，０に調整した。この水ｉＷ ｍを精製水
で全ａ ｌｏｏｍｌとし、０．２２μ蒙メンブランフ
ィルターでろ適役、！！菌的にｌ（１ｍ１点眼容器に充
填し、施栓して点眼剤とした。(Example 1) Dissolve 1 g of sodium chondroitin sulfate and loo II in purified water, and add 250 ml of dipotassium glycyrrhizinate to the purified water.
After dissolving g, benzalkonium chloride 10% water NHO
, 1 ml was added. This L aminoethyl sulfonic acid 500mz, bow #1. Og was dissolved and an appropriate amount of borax was added to adjust the pH to 7.0. This water iW m is made up to a room ml with purified water, and filtered through a 0.22 μm membrane filter. ! Filled into a 1 ml eye drop container and sealed with a stopper to make an eye drop.
（実施例２）
コンドロイチン硫酸ナトリウム１００ｍｇを精製水に護
解しこれにニラコールＨＣ０６０１００ｍｇを溶解した
後、塩化ヘンザルコニウ１．１０％水溶液０．１１を添
加した。これにメチル硫酸ネオスチグミン２ｓｏｍｇ、
ホウ酸 １．０．ｇを溶解し、ホウ砂の適１を加え ｐ
Ｈ７，０に調整した。以下、実施例１と同様に操作して
点眼剤とした。(Example 2) After 100 mg of sodium chondroitin sulfate was dissolved in purified water and 100 mg of Nylacol HC060 was dissolved therein, 0.11 g of a 1.10% aqueous solution of henzalkonium chloride was added. To this, 2 somg of neostigmine methyl sulfate,
Boric acid 1.0. Dissolve g, add 1 tablespoon of borax, p
Adjusted to H7.0. Thereafter, the same procedure as in Example 1 was performed to obtain an eye drop.
（実施例３）
コンドロイチン硫酸ナトリウノ・ ｌ ００ｍｇを精製
水に溶解しこれにニラコールＴＯＩＯＭ ｌｏｏｍｇ
を溶解した後、塩化ヘンプルコニウム１０％水溶液０．
１１を？１強崩した。これにフラビンアデニンジヌクレ
オチド ２０ＩＩ１ｇ１ ホウ酸 １．０ｇを、７ノ
解し、ホウ砂のａ量を加え ｐＨ７，０に調整した。以
下、実施例１と同様に操作して点眼剤とした。(Example 3) Dissolve 00mg of sodium chondroitin sulfate in purified water and add Niracol TOIOM loomg to it.
After dissolving 0.0% hempulkonium chloride aqueous solution.
11? I lost a strong one. To this was dissolved 1 g of flavin adenine dinucleotide 20II, 1.0 g of boric acid, and an amount of borax was added to adjust the pH to 7.0. Thereafter, the same procedure as in Example 1 was performed to obtain an eye drop.
（実施例４）
コンドロイチン硫酸ナトリウ１．２００ｍｇを精製水に
溶解しこれにニラコールＭＹ５ ４０ １００ｍｇを溶
解した後、塩化ベンザルコニウム１０％水溶液０ｍ１を
ン、昏加した１女これにフラビンアデニンジヌクレオチ
ド ２０ｍｇ、ホウ酸 ＋、ｏｇを溶解し、精製水で全
量 １００ｍ１とし、ホウ砂の適量を加え ρ８７．０
に調製した。以下、実施例１と同様に操作して点眼＾り
と し た。(Example 4) After dissolving 1.200 mg of sodium chondroitin sulfate in purified water and dissolving 100 mg of Nilacol MY5 40 therein, 0 ml of a 10% aqueous solution of benzalkonium chloride was added to the flavin adenine dinucleotide. Dissolve 20mg, boric acid +, og, make the total volume 100ml with purified water, add an appropriate amount of borax, ρ87.0
It was prepared as follows. Thereafter, the same procedure as in Example 1 was performed to apply the eye drops.
（実施例５）
コンドロイチン硫酸ナトリウム２００Ｂを精製水に溶解
しこれにグリチルリチン酸モノアンモニウム１００ｍｇ
を溶解した後、塩化ヘンザルコニウｌ＊ １０％水ｉ’
ａｉ＆ ０．！ｍｌを添加した後これにエデト酸ナトリ
ウｌい ５＋Ｂ、ホウ酸 １．０ｇを溶解し、精製水で
全量１００ｍ ｌとし、ホウ砂のＩＩ！！量を加え ｐ
Ｉ＋ ７ 、０に調製した。以下、実施例１と同様に
操作して点眼剤とした。(Example 5) Sodium chondroitin sulfate 200B was dissolved in purified water, and 100 mg of monoammonium glycyrrhizinate was added to the solution.
After dissolving henzalkonium chloride l* 10% water i'
ai & 0. ! ml of borax, then dissolve edetate sodium 5+B and 1.0 g of boric acid, make up the total volume to 100 ml with purified water, and add borax II! ! Add the amount p
I+7, adjusted to 0. Thereafter, the same procedure as in Example 1 was performed to obtain an eye drop.
（実らセ例６）
コンドロイチン６９ Ｍナトリウム２００市ｇを精製水
に、？Ｉ解しこれにプルロニフクＦ ６８ １００ｍｇ
を１容解した後、塩化ベンゼトニウム１０％水溶液０．
１１を添加い これにエデト酸ナトリウム ５ｍｇ、ホ
ウ酸１．０ｇを溶解し、精製水で全＠ １００ｍ１と
し、ボウ砂のａｆｔを加え ｐ Ｉ＋ ７ 、０に調製
した。以下、実施例１と同様に操作して点眼剤とした。(Example 6) Add 200 g of chondroitin 69 M sodium to purified water. I understand this and Pluronifuku F 68 100mg
After dissolving 1 ml of benzethonium chloride, add 0.0 ml of a 10% aqueous solution of benzethonium chloride.
11 was added thereto. 5 mg of sodium edetate and 1.0 g of boric acid were dissolved therein, the total volume was made up to 100 ml with purified water, and aft of sand was added to adjust the p I+ to 7.0. Thereafter, the same procedure as in Example 1 was performed to obtain an eye drop.
（比較例）
コンドロイチン硫酸ナトリウｌ＝ ２００ ｍ ｙ、を
精製水に溶解し、塩化ヘンザルコニウム１０％水溶液０
１１を添加した後これ（こアミノエチルスルボン酸５０
０ｍｇ、ホウ酸 １．Ｏｇを溶解し、精製水で全量１０
０ｍ１とし、ホウ砂のａｔｔを加え ｐＨ７，０に調製
した。(Comparative example) Chondroitin sulfate sodium l = 200 m y was dissolved in purified water, and henzalkonium chloride 10% aqueous solution 0
After adding 11, this (aminoethyl sulfonic acid 50
0mg, boric acid 1. Dissolve Og and add purified water to a total volume of 10
The pH was adjusted to 0ml, and borax att was added to adjust the pH to 7.0.
以下、実施例１と同様に操作して点眼剤とした。Thereafter, the same procedure as in Example 1 was performed to obtain an eye drop.
［作用］
ｌ）各実施例において、メンブランフィルタ−でろ過す
る前の水溶液の外観を観察したＰｉ東を表１ にボす。[Function] l) In each Example, the appearance of the aqueous solution before being filtered with a membrane filter is shown in Table 1.
表 １ ： 澄明であった 表２ ＋： 白濁または沈澱を認めた。Table 1 : It was clear Table 2 +: White turbidity or precipitation was observed.
２）また製造直後及び経時試験後の外観を観察した結果
を表２に示す。2) Table 2 also shows the results of observing the appearance immediately after manufacture and after the aging test.
（以下余白） ： 澄明であった。(Margin below) : It was clear.
＋： 白；訂または沈、幻を認めた。+: White; correction or shedding, recognized the illusion.
手続補正書（自発）
平成１年１月１７日
比較例では製造直後から白濁及び沈、澱を生じたのに対
して、実施例ではいずれも安定であった。Procedural Amendment (Voluntary) January 17, 1999 In the Comparative Example, cloudiness, precipitation, and sludge formed immediately after production, whereas in the Examples, all were stable.
［ブを明の効ｌ！！］
本発明は塩（ヒベンザルコニウム、塩化ベンゼトニウム
なとの第４級アンモニウム塩類とコンドロイチン硫酸ナ
トリウムを配合した点眼剤であり白濁、ＦｊＳ：Ｑを防
止し安定な点眼剤として包めて有用である。[The effect of light! ! ] The present invention is an eye drop containing quaternary ammonium salts such as salts (hibenzalkonium, benzethonium chloride, etc.) and sodium chondroitin sulfate, which prevents clouding and FjS:Q and is useful as a stable eye drop. .
出願人 ゼリア新薬工業株式会社
特許庁長官 吉 １） 文 毅 殿
１、＄件の表示
昭和６３年特許願第２３３５６ ＝１号２、発明の名称
安定な点眼剤
３、補正をする者
事件との関係 特許出、＠人
東京都中央区日本橋小舟町１０番１１号電話 ０３ （
６６１）０２７６
５、補正により増加する請求項の数
なし
７、補正の内容
（１）明細書の特許請求の範囲を別紙のとおり補正しま
す。Applicant Zeria Pharmaceutical Industries Co., Ltd. Commissioner of the Patent Office Yoshi 1) Moon Takeshi 1, Indication of $ 1985 Patent Application No. 23356 = 1 2, Name of the invention: Stable eye drops 3, Compliance with the person making the amendment Related patent issue, @person, 10-11 Kobune-cho, Nihonbashi, Chuo-ku, Tokyo Telephone 03 (
661)0276 5. No number of claims increased due to amendment 7. Contents of amendment (1) The scope of claims in the specification will be amended as shown in the attached sheet.
（２）明細書第７頁第６〜７行、同第８頁第１３〜１４
行および同第９頁第１〜２行の「フラビンアデニンジヌ
クレオチド」をそれぞれ「フラビンアデニンジヌクレオ
チドナトリウム」に補正します。(2) Page 7 lines 6-7 of the specification, page 8 lines 13-14
Correct "flavin adenine dinucleotide" in rows and lines 1 and 2 of page 9 to "flavin adenine dinucleotide sodium" respectively.
（３）同第８頁第６行のｒ２５０ｍｇＪをｒ５ｍｇ」に
補正します。(3) Correct r250mgJ on page 8, line 6 to r5mg.
（４〉同第９頁第４１１．同第９頁第１２１〒、同第１
０頁第１行および同第１０頁第８行の「調製」をそれぞ
れ「調整」に補正します。(4) Ibid., p. 9, No. 411. Ibid., p. 9, No. 121, Ibid., No. 1
Correct "preparation" in line 1 of page 0 and line 8 of page 10 to "adjustment".
（５）同第１３頁第３行の「製造直後」を「成分混合直
後」に補正します。(5) Correct "immediately after manufacture" in the third line of page 13 to "immediately after mixing the ingredients."
別紙
２、特許請求の範囲
（１）第４′ｇ１アンモニウム塩類及びコンドロイチン
硫酸ナトリウムを配合する点眼剤において、グリチルリ
チン酸またはその塩を配合することを特徴とする点眼剤
。Attachment 2, Claims (1) Eye drops containing 4'g1 ammonium salts and sodium chondroitin sulfate, characterized in that they contain glycyrrhizic acid or a salt thereof.
（２）グリチルリチン酸またはその塩を０．０１〜０．
５ｗ／ｖ％の割合で配合する請求項（１）記載の点眼剤
。(2) Glycyrrhizic acid or its salt at 0.01-0.
The eye drops according to claim (1), which is blended at a ratio of 5 w/v%.
（３）第４級アンモニウム塩類及びコンドロイチン硫酸
ナトリウムを配合する点眼剤において、よりオキシエチ
レン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪
酸エステル、ポリオキシエチレン脂肪酸エステルまたは
ポリオキシエチレンポリオキシプロピレンエーテルの中
から選はれた１種または２種以上を配合することを特徴
とする点眼剤。(3) Eye drops containing quaternary ammonium salts and sodium chondroitin sulfate, selected from oxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, or polyoxyethylene polyoxypropylene ether. An eye drop containing one or more types of eye drops.
（４）ポリオキシエチレン硬化ヒマシ浦、ポリオキシエ
チレンソルビタン脂肪酸エステル、ポリオキシエチレン
脂肪酸エステルまたはポリオキシエチレンポリオキシプ
ロピレンエーテルの中から退ばれた１種または２ｐｊ以
上を０．０１〜０．５ｗ／ｖ％の割合で配合する請求項
（３）記載の点眼剤。(4) 0.01 to 0.5 w/at least one type or 2 pj or more of polyoxyethylene hardened castor uranium, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, or polyoxyethylene polyoxypropylene ether. The eye drops according to claim (3), wherein the eye drops are blended in a proportion of v%.
（５）第４級アンモニウム塩類が塩化ベンザルコニウム
または塩化・＼ンゼトニウムである請求項（１）または
請求項（３）記載の点眼剤。(5) The eye drops according to claim (1) or claim (3), wherein the quaternary ammonium salt is benzalkonium chloride or zethonium chloride.
（６）第４級アンモニウム塩類を０．００１〜０゜０２
ｗ／ｖ％、 コンドロイチン硫酸ナトリウムを００５
〜０．５ｗ／ｖ％の割合で配合する請求項（１）又は請
求項（３）記載の点眼剤。(6) Quaternary ammonium salts from 0.001 to 0°02
w/v%, sodium chondroitin sulfate 005
The eye drops according to claim (1) or claim (3), which is blended in a proportion of ~0.5 w/v%.
Claims (6)
ナトリウムを配合する点眼剤において、グリチルリチン
酸またはその塩を配合することを特徴とする点眼剤。(1) Eye drops containing quaternary ammonium salts and sodium chondroitin sulfate, characterized in that they contain glycyrrhizic acid or a salt thereof.
５ｗ／ｖ％の割合で配合する請求項（１）記載の点眼剤
。(2) Glycyrrhizic acid or its salt at 0.01-0.
The eye drops according to claim (1), which is blended at a ratio of 5 w/v%.
ナトリウムを配合する点眼剤において、ポリオキシエチ
レン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪
酸エステル、ポリオキシエチレン脂肪酸エステルまたは
ポリオキシエチレンポリオキシプロピレンエーテルの中
から選ばれた１種または２種以上を配合することを特徴
とする点眼剤。(3) Eye drops containing quaternary ammonium salts and sodium chondroitin sulfate, selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, or polyoxyethylene polyoxypropylene ether. An eye drop containing one or more of the above.
チレンソルビタン脂肪酸エステル、ポリオキシエチレン
脂肪酸エステルまたはポリオキシエチレンポリオキシプ
ロピレンエーテルの中から選ばれた１種または２種以上
を０．０１〜０．５ｗ／ｖ％の割合で配合する請求項（
３）記載の点眼剤。(4) 0.01 to 0.5w of one or more selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, or polyoxyethylene polyoxypropylene ether /v% of the claim (
3) Eye drops as described.
または塩化ベンゼトニウムである請求項（１）または請
求項（３）記載の点眼剤。(5) The eye drops according to claim (1) or claim (3), wherein the quaternary ammonium salt is benzalkonium chloride or benzethonium chloride.
ｖ％、コンドロイチン硫酸ナトリウムを０．０５〜０．
５ｗ／ｖ％の割合で配合する請求項（１）又は請求項（
３）記載の点眼剤。(6) 0.01 to 0.2 w/quaternary ammonium salts
v%, sodium chondroitin sulfate from 0.05 to 0.
Claim (1) or claim (
3) Eye drops as described.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63233564A JPH0283318A (en) | 1988-09-20 | 1988-09-20 | Stable eye drop |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63233564A JPH0283318A (en) | 1988-09-20 | 1988-09-20 | Stable eye drop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0283318A true JPH0283318A (en) | 1990-03-23 |
Family
ID=16957047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63233564A Pending JPH0283318A (en) | 1988-09-20 | 1988-09-20 | Stable eye drop |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0283318A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5662919A (en) * | 1994-11-21 | 1997-09-02 | Alcon Laboratories, Inc. | Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds |
| WO2000016774A1 (en) * | 1998-09-18 | 2000-03-30 | Senju Pharmaceutical Co., Ltd. | Method for solubilizing pyridonecarboxylic acid, solubilizer therefor, aqueous solution preparations containing pyridonecarboxylic acid and process for producing the same |
| JP2000143501A (en) * | 1998-11-12 | 2000-05-23 | Zeria Pharmaceut Co Ltd | Sulfa drug-containing ophthalmic solution |
| JP2001114700A (en) * | 1999-10-14 | 2001-04-24 | Hisamitsu Pharmaceut Co Inc | Eye drop composition |
| FR2849383A1 (en) * | 2002-12-26 | 2004-07-02 | Jean Noel Thorel | TROPHIC COMPOSITION IN AQUEOUS MEDIUM, AND ITS APPLICATIONS, IN PARTICULAR IN OPHTHALMOLOGY |
| JP2005527649A (en) * | 2001-12-12 | 2005-09-15 | ピエール、ファブレ、デルモ‐コスメティーク | Novel combination comprising poloxamer and chondroitin sulfate and / or glycoprotein and use thereof |
| JP2005247795A (en) * | 2004-03-08 | 2005-09-15 | Zeria Pharmaceut Co Ltd | Stable eye drops |
| WO2014119643A1 (en) * | 2013-01-31 | 2014-08-07 | 千寿製薬株式会社 | Clear aqueous solution |
| JP2022179821A (en) * | 2021-05-17 | 2022-12-05 | ロート製薬株式会社 | ophthalmic composition |
-
1988
- 1988-09-20 JP JP63233564A patent/JPH0283318A/en active Pending
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5662919A (en) * | 1994-11-21 | 1997-09-02 | Alcon Laboratories, Inc. | Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds |
| WO2000016774A1 (en) * | 1998-09-18 | 2000-03-30 | Senju Pharmaceutical Co., Ltd. | Method for solubilizing pyridonecarboxylic acid, solubilizer therefor, aqueous solution preparations containing pyridonecarboxylic acid and process for producing the same |
| US6306856B1 (en) | 1998-09-18 | 2001-10-23 | Senju Pharmaceutical Co., Ltd. | Method for solubilizing pyridonecarboxylic acid, solubilizer therefor, aqueous solution preparation containing pyridonecarboxylic acid and process for producing the same |
| JP4681734B2 (en) * | 1998-09-18 | 2011-05-11 | 千寿製薬株式会社 | Method for solubilizing pyridonecarboxylic acid, solubilizer, aqueous solution containing pyridonecarboxylic acid, and method for producing the same |
| JP2000143501A (en) * | 1998-11-12 | 2000-05-23 | Zeria Pharmaceut Co Ltd | Sulfa drug-containing ophthalmic solution |
| JP2001114700A (en) * | 1999-10-14 | 2001-04-24 | Hisamitsu Pharmaceut Co Inc | Eye drop composition |
| JP2005527649A (en) * | 2001-12-12 | 2005-09-15 | ピエール、ファブレ、デルモ‐コスメティーク | Novel combination comprising poloxamer and chondroitin sulfate and / or glycoprotein and use thereof |
| JP4786869B2 (en) * | 2001-12-12 | 2011-10-05 | ピエール、ファブレ、デルモ‐コスメティーク | Novel combination comprising poloxamer and chondroitin sulfate and / or glycoprotein and use thereof |
| US8435503B2 (en) | 2002-12-26 | 2013-05-07 | Jean-Noel Thorel | Ophthalmic and ophthalmological use of a complex nutritive base in aqueous medium |
| FR2849383A1 (en) * | 2002-12-26 | 2004-07-02 | Jean Noel Thorel | TROPHIC COMPOSITION IN AQUEOUS MEDIUM, AND ITS APPLICATIONS, IN PARTICULAR IN OPHTHALMOLOGY |
| WO2004060348A3 (en) * | 2002-12-26 | 2004-09-23 | Jean-Noel Thorel | Ophthalmic and ophthalmological use of a complex nutritive base in an aqueous medium |
| JP2005247795A (en) * | 2004-03-08 | 2005-09-15 | Zeria Pharmaceut Co Ltd | Stable eye drops |
| WO2014119643A1 (en) * | 2013-01-31 | 2014-08-07 | 千寿製薬株式会社 | Clear aqueous solution |
| JP5753958B2 (en) * | 2013-01-31 | 2015-07-22 | 千寿製薬株式会社 | Clear aqueous solution |
| US9968679B2 (en) | 2013-01-31 | 2018-05-15 | Senju Pharmaceutical Co., Ltd. | Clear aqueous solution |
| US10709786B2 (en) | 2013-01-31 | 2020-07-14 | Senju Pharmaceutical Co., Ltd. | Clear aqueous solution |
| JP2022179821A (en) * | 2021-05-17 | 2022-12-05 | ロート製薬株式会社 | ophthalmic composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60030682T2 (en) | TWO-PARTICULAR BICARBONATE SOLUTION FOR PERITONEAL DIALYSIS OR AS A SUBSTITUTION SOLUTION FOR CONTINUOUS NOISE SUBSTITUTION THERAPY | |
| AU2002356899B2 (en) | Bicarbonate-based solutions for dialysis therapies | |
| DE03758361T1 (en) | DARM CLEANER COMPOSITION | |
| JPS62123116A (en) | Aqueous solution agent | |
| JP2003517463A (en) | Disinfection compositions based on H2O2, acids and metal ions | |
| CA2290461A1 (en) | Antiseptic composition | |
| JP2009538287A5 (en) | Compositions composed of low viscosity glycosaminoglycans and their use in the treatment of interstitial cystitis | |
| JPH0283318A (en) | Stable eye drop | |
| JPH085800B2 (en) | Aqueous formulation containing lysozyme chloride and dipotassium glycyrrhizinate | |
| WO1996032941A1 (en) | Pranoprofen eyedrops containing organic amine | |
| CN101987109B (en) | Ophthalmic composition containing povidone iodine and cyclodextrin included glucocorticoid | |
| CN101123957B (en) | Diclofenac and Injectable preparations of pharmaceutically acceptable salts of diclofenac | |
| JP4355574B2 (en) | Eye drops | |
| CN102670648B (en) | Liquid iodine disinfectant, preparation method and used container thereof | |
| JP4806956B2 (en) | Ophthalmic solution | |
| JP4442118B2 (en) | Stable eye drops | |
| CN102335128A (en) | Formula and preparation method of iodine complex solution | |
| JPH02304026A (en) | Liquid for peritoneal lavage | |
| JPH075456B2 (en) | Eye drops | |
| US20150174245A1 (en) | Transparent gel | |
| JPH0129170B2 (en) | ||
| JP4157988B2 (en) | Water-soluble preparations with no contraindications | |
| CN110200905A (en) | A kind of ambroxol hydrochloride composition and its injection and application | |
| JPS63297322A (en) | Production of stable ophthalmic solution containing sodium guaiazulenesulfonate | |
| JPH02164829A (en) | Instillation containing hyaluronic acid |